الفهرس 
الغلافOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Background: Warts constitute the commonest cutaneous manifestation of
human papilloma virus (HPV) infection. A variety of procedures has been
used and treatment may be invasive and/or conservative. In this study we
compared the efficacy and safety of intralesional Candida antigen injection
and contact diphencyclopropenone (DPCP) in the treatment of common
warts.
Methods: Fourty patients with common warts were randomly divided into
two groups. One group received intralesional injection of candida antigen
repeated every 3 weeks until complete improvement of all warts or for a
maximum of three sessions. The second group was treated weekly by contact
DPCP for a maximum of five sessions or until clearance of all lesions. T-test
and chi-square test were used for statistical analysis, and P < 0.05 was
considered statistically significant.
Results: The patients showed better therapeutic response to intralesional
candida vaccine than contact DPCP but it was not significant (p value=0.139).
Our findings showed that candida antigen was effective with response rate
81.25 %, where 60% of patients showed complete clearance of central treated
wart, while 18.1% of patients showed clearance of adjacent warts. On the
other hand, DPCP was shown to be also effective in treatment of warts with a
response rate of 50%, where 25% of patients showed complete clearance of
central treated wart, but no clearance of adjacent warts. 40% of patients in the
candida antigen group suffered side effects of treatment in comparison to
100% of patients in the DPCP group and this difference was statistically
significant (p value= 0.002). For the candida antigen group, treatment failure
was significantly higher among patients with longer wart duration (p value =
0.022), which was not observed in the DPCP group.